{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:39:32Z","timestamp":1790419172529,"version":"4.1.0"},"reference-count":54,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Chagas disease, caused by the protozoan Trypanosoma cruzi is a neglected tropical disease\nwith high prevalence (5.7 million in Latin America, WHO 2015), significant burden, and significant\nmorbimortality mostly due to severe heart disorders during the chronic phase of infection.\nChagas disease is endemic in Latin America, and medical care for the disease is the major expense\nfor Brazil\u2019s Universal Healthcare System (Sistema \u00danico de Sa\u00fade (SUS). The efficacy of the available\ndrugs benznidazole and nifurtimox are low for the chronic phase of Chagas disease, the phase\nin which most patients are diagnosed, and there are frequent side effects, and drug resistance occurs.\nThe rapid deployment of new drug regimens that are effective for the chronic phase treatment\nis low-cost and less toxic than the currently available therapy, which is a global priority. Repurposing\ndrugs already in clinical use with other combinations would be the fastest and safest strategy\nfor treating Chagas disease patients. We hypothesize that the combined treatment using repurposing\ndrugs with benznidazole will be more efficacious than benznidazole alone. This needs to be tested\nfurther both in vitro and in animal models to understand the efficacy of the treatment before performing\nhuman clinical trials. We further hypothesize that producing nanoparticle formulation of\nthe drugs can reduce their toxicity and improve therapeutic use.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121999201124122643","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T10:30:50Z","timestamp":1606732250000},"page":"835-841","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["New Approaches for the Treatment of Chagas Disease"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5196-6468","authenticated-orcid":true,"given":"Ramendra Pati","family":"Pandey","sequence":"first","affiliation":[{"name":"Centre for Drug Design Discovery and Development (C4D), SRM University, DelhiNCR, Rajiv Gandhi Education City, Sonepat - 131 029, Haryana,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilda Savoia","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Laboratorio de Imunologia, Instituto do Coracao, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo,Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrin E.","family":"Moore","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery Old Road Campus, Headington, Oxford, OX3 7LF,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Samuel","family":"Raj","sequence":"additional","affiliation":[{"name":"Centre for Drug Design Discovery and Development (C4D), SRM University, DelhiNCR, Rajiv Gandhi Education City, Sonepat - 131 029, Haryana,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Kalil","sequence":"additional","affiliation":[{"name":"Laboratorio de Imunologia, Instituto do Coracao, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo,Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edecio","family":"Cunha-Neto","sequence":"additional","affiliation":[{"name":"Laboratorio de Imunologia, Instituto do Coracao, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo,Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"348","DOI":"10.5935\/abc.20180038","volume":"110","author":"Nascimento M.S.","year":"2018","unstructured":"Nascimento M.S.; Stolf A.M.S.; Andrade Junior H.F.; Pandey R.P.; Umezawa E.S.; Vimentin and anti vimentin antibodies in chagas\u2019 disease. Arq Bras Cardiol 2018,110(4),348-353","journal-title":"Arq Bras Cardiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.3389\/fimmu.2018.02791","volume":"9","author":"Chevillard C.","year":"2018","unstructured":"Chevillard C.; Nunes J.P.S.; Frade A.F.; Almeida R.R.; Pandey R.P.; Nascimento M.S.; Kalil J.; Cunha-Neto E.; Disease tolerance and pathogen resistance genes may underlie Trypanosoma cruzi persistence and differential progression to chagas disease cardiomyopathy. Front Immunol 2018,9,2791","journal-title":"Front Immunol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"17990","DOI":"10.1038\/s41598-017-18080-9","volume":"7","author":"Ferreira L.R.P.","year":"2017","unstructured":"Ferreira L.R.P.; Ferreira F.M.; Laugier L.; Cabantous S.; Navarro I.C.; da Silva C\u00e2ndido D.; Rigaud V.C.; Real J.M.; Pereira G.V.; Pereira I.R.; Ruivo L.; Pandey R.P.; Savoia M.; Kalil J.; Lannes-Vieira J.; Nakaya H.; Chevillard C.; Cunha-Neto E.; Integration of miRNA and gene expression profiles suggest a role for miRNAs in the pathobiological processes of acute Trypanosoma cruzi infection. Sci Rep 2017,7(1),17990","journal-title":"Sci Rep"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.csbj.2016.12.002","volume":"15","author":"Chatelain E.","year":"2016","unstructured":"Chatelain E.; Chagas disease research and development: Is there light at the end of the tunnel? Comput Struct Biotechnol J 2016,15,98-103","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=5","unstructured":"Available from:"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2174\/138955751503150312120208","volume":"15","author":"Bellera C.L.","year":"2015","unstructured":"Bellera C.L.; Sbaraglini M.L.; Balcazar D.E.; Fraccaroli L.; Vanrell M.C.; Casassa A.F.; Labriola C.A.; Romano P.S.; Carrillo C.; Talevi A.; High-throughput drug repositioning for the discovery of new treatments for Chagas disease. Mini Rev Med Chem 2015,15(3),182-193","journal-title":"Mini Rev Med Chem"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1537-2995.2006.00715.x","volume":"46","author":"Kirchhoff L.V.","year":"2006","unstructured":"Kirchhoff L.V.; Paredes P.; Lomel\u00ed-Guerrero A.; Paredes-Espinoza M.; Ron-Guerrero C.S.; Delgado-Mej\u00eda M.; Pe\u00f1a-Mu\u00f1oz J.G.; Transfusion-associated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States. Transfusion 2006,46(2),298-304","journal-title":"Transfusion"},{"key":"ref=8","unstructured":"Available from:"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1590\/S0074-02761999000700064","volume":"94","author":"Can\u00e7ado J.R.","year":"1999","unstructured":"Can\u00e7ado J.R.; Criteria of Chagas disease cure. Mem Inst Oswaldo Cruz 1999,94(Suppl. 1),331-335","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","volume":"373","author":"Morillo C.A.","year":"2015","unstructured":"Morillo C.A.; Marin-Neto J.A.; Avezum A.; Sosa-Estani S.; Rassi A.; Rosas F.; Villena E.; Quiroz R.; Bonilla R.; Britto C.; Guhl F.; Velazquez E.; Bonilla L.; Meeks B.; Rao-Melacini P.; Pogue J.; Mattos A.; Lazdins J.; Rassi A.; Connolly S.J.; Yusuf S.; Randomized Trial of Benznidazole for Chronic Chagas\u2019 Cardiomyopathy. N Engl J Med 2015,373(14),1295-1306","journal-title":"N Engl J Med"},{"key":"ref=11","first-page":"159","volume":"47","author":"Mart\u00edn U.O.","year":"1987","unstructured":"Mart\u00edn U.O.; Afchain D.; de Marteleur A.; Ledesma O.; Capr\u00f3n A.; [Circulating immune complexes in different developmental stages of Chagas\u2019 disease]. Medicina (B Aires) [Circulating immune complexes in different developmental stages of Chagas' disease].1987,47(2),159-162","journal-title":"Medicina (B Aires)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1590\/S0066-782X2011005000112","volume":"97","author":"Barbosa A.P.","year":"2011","unstructured":"Barbosa A.P.; Cardinalli Neto A.; Otaviano A.P.; Rocha B.F.; Bestetti R.B.; Comparison of outcome between Chagas cardiomyopathy and idiopathic dilated cardiomyopathy. Arq Bras Cardiol 2011,97(6),517-525","journal-title":"Arq Bras Cardiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0167-5273(97)00083-1","volume":"60","author":"Bestetti R.B.","year":"1997","unstructured":"Bestetti R.B.; Muccillo G.; Clinical course of Chagas\u2019 heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol 1997,60(2),187-193","journal-title":"Int J Cardiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/clc.4960101113","volume":"10","author":"Higuchi M.L.","year":"1987","unstructured":"Higuchi M.L.; De Morais C.F.; Pereira Barreto A.C.; Lopes E.A.; Stolf N.; Bellotti G.; Pileggi F.; The role of active myocarditis in the development of heart failure in chronic Chagas\u2019 disease: a study based on endomyocardial biopsies. Clin Cardiol 1987,10(11),665-670","journal-title":"Clin Cardiol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1590\/S0074-02762009000900032","volume":"104","author":"Cunha-Neto E.","year":"2009","unstructured":"Cunha-Neto E.; Nogueira L.G.; Teixeira P.C.; Ramasawmy R.; Drigo S.A.; Goldberg A.C.; Fonseca S.G.; Bilate A.M.; Kalil J.; Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy. Mem Inst Oswaldo Cruz 2009,104(Suppl. 1),252-258","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1159\/000175035","volume":"80","author":"Milei J.","year":"1992","unstructured":"Milei J.; Storino R.; Fernandez Alonso G.; Beigelman R.; Vanzulli S.; Ferrans V.J.; Endomyocardial biopsies in chronic chagasic cardiomyopathy. Immunohistochemical and ultrastructural findings. Cardiology 1992,80(5-6),424-437","journal-title":"Cardiology"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF01614765","volume":"423","author":"Higuchi Mde.L.","year":"1993","unstructured":"Higuchi Mde.L.; Gutierrez P.S.; Aiello V.D.; Palomino S.; Bocchi E.; Kalil J.; Bellotti G.; Pileggi F.; Immunohistochemical characterization of infiltrating cells in human chronic chagasic myocarditis: comparison with myocardial rejection process. Virchows Arch A Pathol Anat Histopathol 1993,423(3),157-160","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.4269\/ajtmh.1993.48.637","volume":"48","author":"Reis D.D.","year":"1993","unstructured":"Reis D.D.; Jones E.M.; Tostes S.; Lopes E.R.; Gazzinelli G.; Colley D.G.; McCurley T.L.; Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of tumor necrosis factor-alpha+ cells and dominance of granzyme A+, CD8+ lymphocytes. Am J Trop Med Hyg 1993,48(5),637-644","journal-title":"Am J Trop Med Hyg"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1006\/jaut.2001.0523","volume":"17","author":"Abel L.C.","year":"2001","unstructured":"Abel L.C.; Rizzo L.V.; Ianni B.; Albuquerque F.; Bacal F.; Carrara D.; Bocchi E.A.; Teixeira H.C.; Mady C.; Kalil J.; Cunha-Neto E.; Chronic Chagas\u2019 disease cardiomyopathy patients display an increased IFN-gamma response to Trypanosoma cruzi infection. J Autoimmun 2001,17(1),99-107","journal-title":"J Autoimmun"},{"key":"ref=20","first-page":"361730","volume":"2012","author":"Rocha Rodrigues D.B.","year":"2012","unstructured":"Rocha Rodrigues D.B.; dos Reis M.A.; Romano A.; Pereira S.A.; Teixeira Vde.P.; Tostes S.; Rodrigues V.; In situ expression of regulatory cytokines by heart inflammatory cells in Chagas\u2019 disease patients with heart failure. Clin Dev Immunol 2012,2012,361730","journal-title":"Clin Dev Immunol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"914326","DOI":"10.1155\/2014\/914326","volume":"2014","author":"Nogueira L.G.","year":"2014","unstructured":"Nogueira L.G.; Santos R.H.; Fiorelli A.I.; Mairena E.C.; Benvenuti L.A.; Bocchi E.A.; Stolf N.A.; Kalil J.; Cunha-Neto E.; Myocardial gene expression of T-bet, GATA-3, Ror-\u03b3t, FoxP3, and hallmark cytokines in chronic Chagas disease cardiomyopathy: an essentially unopposed TH1-type response. Mediators Inflamm 2014,2014,914326","journal-title":"Mediators Inflamm"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0002-9440(10)62976-8","volume":"167","author":"Cunha-Neto E.","year":"2005","unstructured":"Cunha-Neto E.; Dzau V.J.; Allen P.D.; Stamatiou D.; Benvenutti L.; Higuchi M.L.; Koyama N.S.; Silva J.S.; Kalil J.; Liew C.C.; Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas\u2019 disease cardiomyopathy. Am J Pathol 2005,167(2),305-313","journal-title":"Am J Pathol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1172\/JCI118969","volume":"98","author":"Cunha-Neto E.","year":"1996","unstructured":"Cunha-Neto E.; Coelho V.; Guilherme L.; Fiorelli A.; Stolf N.; Kalil J.; Autoimmunity in Chagas\u2019 disease. Identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas\u2019 cardiomyopathy patient. J Clin Invest 1996,98(8),1709-1712","journal-title":"J Clin Invest"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.micinf.2005.01.001","volume":"7","author":"Fonseca S.G.","year":"2005","unstructured":"Fonseca S.G.; Moins-Teisserenc H.; Clave E.; Ianni B.; Nunes V.L.; Mady C.; Iwai L.K.; Sette A.; Sidney J.; Marin M.L.; Goldberg A.C.; Guilherme L.; Charron D.; Toubert A.; Kalil J.; Cunha-Neto E.; Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8+ epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients. Microbes Infect 2005,7(4),688-697","journal-title":"Microbes Infect"},{"key":"ref=25","first-page":"2471","volume":"45","author":"Docampo R.","year":"1986","unstructured":"Docampo R.; Moreno S.N.; Free radical metabolism of antiparasitic agents. Fed Proc 1986,45(10),2471-2476","journal-title":"Fed Proc"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0009-2797(90)90106-W","volume":"73","author":"Docampo R.","year":"1990","unstructured":"Docampo R.; Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem Biol Interact 1990,73(1),1-27","journal-title":"Chem Biol Interact"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e2844","DOI":"10.1371\/journal.pntd.0002844","volume":"8","author":"Trochine A.","year":"2014","unstructured":"Trochine A.; Creek D.J.; Faral-Tello P.; Barrett M.P.; Robello C.; Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics. PLoS Negl Trop Dis 2014,8(5),e2844","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/em.21839","volume":"55","author":"Raj\u00e3o M.A.","year":"2014","unstructured":"Raj\u00e3o M.A.; Furtado C.; Alves C.L.; Passos-Silva D.G.; de Moura M.B.; Schamber-Reis B.L.; Kunrath-Lima M.; Zuma A.A.; Vieira-da-Rocha J.P.; Garcia J.B.; Mendes I.C.; Pena S.D.; Macedo A.M.; Franco G.R.; de Souza-Pinto N.C.; de Medeiros M.H.; Cruz A.K.; Motta M.C.; Teixeira S.M.; Machado C.R.; Unveiling benznidazole\u2019s mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi. Environ Mol Mutagen 2014,55(4),309-321","journal-title":"Environ Mol Mutagen"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1590\/S0074-02762002000100001","volume":"97","author":"Rodriques Coura J.","year":"2002","unstructured":"Rodriques Coura J.; de Castro S.L.; A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002,97(1),3-24","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/cid\/civ005","volume":"60","author":"Miller D.A.","year":"2015","unstructured":"Miller D.A.; Hernandez S.; Rodriguez De Armas L.; Eells S.J.; Traina M.M.; Miller L.G.; Meymandi S.K.; Tolerance of benznidazole in a United States Chagas Disease clinic. Clin Infect Dis 2015,60(8),1237-1240","journal-title":"Clin Infect Dis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/0035-9203(87)90020-4","volume":"81","author":"Filardi L.S.","year":"1987","unstructured":"Filardi L.S.; Brener Z.; Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 1987,81(5),755-759","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0166-6851(98)00037-1","volume":"93","author":"Murta S.M.","year":"1998","unstructured":"Murta S.M.; Gazzinelli R.T.; Brener Z.; Romanha A.J.; Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol 1998,93(2),203-214","journal-title":"Mol Biochem Parasitol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1590\/0074-0276140156","volume":"109","author":"Zingales B.","year":"2014","unstructured":"Zingales B.; Miles M.A.; Moraes C.B.; Luquetti A.; Guhl F.; Schijman A.G.; Ribeiro I.; Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem Inst Oswaldo Cruz 2014,109(6),828-833","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1128\/AAC.49.4.1521-1528.2005","volume":"49","author":"Garcia S.","year":"2005","unstructured":"Garcia S.; Ramos C.O.; Senra J.F.; Vilas-Boas F.; Rodrigues M.M.; Campos-de-Carvalho A.C.; Ribeiro-Dos-Santos R.; Soares M.B.; Treatment with benznidazole during the chronic phase of experimental Chagas\u2019 disease decreases cardiac alterations. Antimicrob Agents Chemother 2005,49(4),1521-1528","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1590\/S0074-02761999000700068","volume":"94","author":"Urbina J.A.","year":"1999","unstructured":"Urbina J.A.; Parasitological cure of Chagas disease: is it possible? Is it relevant? Mem Inst Oswaldo Cruz 1999,94(Suppl. 1),349-355","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1128\/AAC.47.6.2047-2050.2003","volume":"47","author":"Urbina J.A.","year":"2003","unstructured":"Urbina J.A.; Concepcion J.L.; Montalvetti A.; Rodriguez J.B.; Docampo R.; Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas\u2019 disease. Antimicrob Agents Chemother 2003,47(6),2047-2050","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1128\/AAC.42.10.2549","volume":"42","author":"Michailowsky V.","year":"1998","unstructured":"Michailowsky V.; Murta S.M.; Carvalho-Oliveira L.; Pereira M.E.; Ferreira L.R.; Brener Z.; Romanha A.J.; Gazzinelli R.T.; Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob Agents Chemother 1998,42(10),2549-2556","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=38","unstructured":"Available from:"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ijpddr.2011.12.002","volume":"2","author":"Buckner F.S.","year":"2012","unstructured":"Buckner F.S.; Urbina J.A.; Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist 2012,2,236-242","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijantimicag.2010.03.006","volume":"36","author":"Olivieri B.P.","year":"2010","unstructured":"Olivieri B.P.; Molina J.T.; de Castro S.L.; Pereira M.C.; Calvet C.M.; Urbina J.A.; Ara\u00fajo-Jorge T.C.; A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int J Antimicrob Agents 2010,36(1),79-83","journal-title":"Int J Antimicrob Agents"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e2367","DOI":"10.1371\/journal.pntd.0002367","volume":"7","year":"2013","unstructured":"Urbina JA, de Andrade IM, Mazzeti AL, Martins TA, Caldas IS, Talvani A, Ribeiro I and Bahia MT. Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLoS Negl Trop Dis 2013,7,e2367","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e2977","DOI":"10.1371\/journal.pntd.0002977","volume":"8","author":"Planer J.D.","year":"2014","unstructured":"Planer J.D.; Hulverson M.A.; Arif J.A.; Ranade R.M.; Don R.; Buckner F.S.; Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi. PLoS Negl Trop Dis 2014,8(7),e2977","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"re8","DOI":"10.1126\/scisignal.129re8","volume":"1","author":"Schwegmann A.","year":"2008","unstructured":"Schwegmann A.; Brombacher F.; Host-directed drug targeting of factors hijacked by pathogens. Sci Signal 2008,1(29),re8","journal-title":"Sci Signal"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/infdis\/jit550","volume":"209","author":"Parihar S.P.","year":"2014","unstructured":"Parihar S.P.; Guler R.; Khutlang R.; Lang D.M.; Hurdayal R.; Mhlanga M.M.; Suzuki H.; Marais A.D.; Brombacher F.; Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 2014,209(5),754-763","journal-title":"J Infect Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.2147\/DDDT.S90208","volume":"9","author":"Chatelain E.","year":"2015","unstructured":"Chatelain E.; Konar N.; Translational challenges of animal models in Chagas disease drug development: a review. Drug Des Devel Ther 2015,9,4807-4823","journal-title":"Drug Des Devel Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.micinf.2003.07.001","volume":"5","author":"Bilate A.M.","year":"2003","unstructured":"Bilate A.M.; Salemi V.M.; Ramires F.J.; de Brito T.; Silva A.M.; Umezawa E.S.; Mady C.; Kalil J.; Cunha-Neto E.; The Syrian hamster as a model for the dilated cardiomyopathy of Chagas\u2019 disease: a quantitative echocardiographical and histopathological analysis. Microbes Infect 2003,5(12),1116-1124","journal-title":"Microbes Infect"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1590\/S0037-86821994000300007","volume":"27","author":"Ram\u00edrez L.E.","year":"1994","unstructured":"Ram\u00edrez L.E.; Lages-Silva E.; Soares J\u00fanior J.M.; Chapadeiro E.; The hamster (Mesocricetus auratus) as experimental model in Chagas\u2019 disease: parasitological and histopathological studies in acute and chronic phases of Trypanosoma cruzi infection. Rev Soc Bras Med Trop 1994,27(3),163-169","journal-title":"Rev Soc Bras Med Trop"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.micinf.2007.05.014","volume":"9","author":"Bilate A.M.","year":"2007","unstructured":"Bilate A.M.; Salemi V.M.; Ramires F.J.; de Brito T.; Russo M.; Fonseca S.G.; Fa\u00e9 K.C.; Martins D.G.; Silva A.M.; Mady C.; Kalil J.; Cunha-Neto E.; TNF blockade aggravates experimental chronic Chagas disease cardiomyopathy. Microbes Infect 2007,9(9),1104-1113","journal-title":"Microbes Infect"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1086\/590347","volume":"198","author":"Bilate A.M.","year":"2008","unstructured":"Bilate A.M.; Teixeira P.C.; Ribeiro S.P.; Brito Td.; Silva A.M.; Russo M.; Kalil J.; Cunha-Neto E.; Distinct outcomes of Trypanosoma cruzi infection in hamsters are related to myocardial parasitism, cytokine\/chemokine gene expression, and protein expression profile. J Infect Dis 2008,198(4),614-623","journal-title":"J Infect Dis"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.6061\/clinics\/2012(09)14","volume":"67","year":"2012","unstructured":"Ramires FJ, Lanni BM, Salemi VM, Bilate AM, Cunha-Neto E, Oliveira AM, Fernandes F and Mady C. The effect of beta-blockade on myocardial remodelling in Chagas\u2019 cardiomyopathy. Clinics (S\u00e3o Paulo) 2012,67,1063-1069","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.cardfail.2012.06.419","volume":"18","author":"Fernandes F.","year":"2012","unstructured":"Fernandes F.; Ramires F.J.; Ianni B.M.; Salemi V.M.; Oliveira A.M.; Pessoa F.G.; Canzian M.; Mady C.; Effect of colchicine on myocardial injury induced by Trypanosoma cruzi in experimental Chagas disease. J Card Fail 2012,18(8),654-659","journal-title":"J Card Fail"},{"key":"ref=52","author":"Tanaka D.M.","year":"2016","unstructured":"Tanaka D.M.;  Estudo do efeito do agente vasodilatador da microcircula\u00e7\u00e3o coronariana sobre os dist\u00farbios de perfus\u00e3o mioc\u00e1rdica e disfun\u00e7\u00e3o ventricular esquerda em modelo de cardiomatia chag\u00e1sica cr\u00f4nica em hamsters 2016","journal-title":"Estudo do efeito do agente vasodilatador da microcircula\u00e7\u00e3o coronariana sobre os dist\u00farbios de perfus\u00e3o mioc\u00e1rdica e disfun\u00e7\u00e3o ventricular esquerda em modelo de cardiomatia chag\u00e1sica cr\u00f4nica em hamsters"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4067\/S0716-97602002000100007","volume":"35","author":"S\u00e1nchez G.","year":"2002","unstructured":"S\u00e1nchez G.; Cuellar D.; Zulantay I.; Gajardo M.; Gonz\u00e1lez-Martin G.; Cytotoxicity and trypanocidal activity of nifurtimox encapsulated in ethylcyanoacrylate nanoparticles. Biol Res 2002,35(1),39-45","journal-title":"Biol Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"388","DOI":"10.4269\/ajtmh.15-0889","volume":"95","author":"Scalise M.L.","year":"2016","unstructured":"Scalise M.L.; Arr\u00faa E.C.; Rial M.S.; Esteva M.I.; Salomon C.J.; Fichera L.E.; Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies. Am J Trop Med Hyg 2016,95(2),388-393","journal-title":"Am J Trop Med Hyg"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450121999201124122643","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/188306\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450121999201124122643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T06:04:41Z","timestamp":1660716281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/188306\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121999201124122643","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}